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Abstract
BACKGROUND: The aim of this study was to assess the prevalence of long bone metastases in renal cancer patients and to 
evaluate their utility as predictors of survival in this group.
MATERIAL AND METHODS: This retrospective study included 20 patients with metastatic renal cancer and bone metastases. 
The patients were referred for regular bone scintigraphy in order to assess disease spread in the skeleton. The patients were 
divided into two groups: those with 1) metastases in the skeleton (including long bones) and those with 2) metastases in the 
axial skeleton only.
RESULTS: Bone scintigraphy imaging was performed regularly up to 81 months from the first positive bone scan. During that 
time 11 deaths (8 among patients with long bone lesions) were recorded. Kaplan-Meyer curves showed that patients with long 
bone metastases tend to have lower survival probability in comparison to the ones with metastases in other bones.
CONCLUSIONS: Bone metastases localization seems to influence survival in patients with renal cancer. Long bone-involving 
spread of the disease is associated with worse survival probability than the spread to the other bones.
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Background
Renal cancer is the 7th most common cancer in Poland, ac-
counting for around 4% of all new cases in males and 3% in females. 
In 2010 in Poland renal cancer was diagnosed in over 2700 men and 
1900 women [1]. The overall 5-year survival rate is approximately 
45% [2]. However, it strongly depends on the stage of the disease 
at the moment of diagnosis — it reaches 80% in patients with local-
ized disease and is as low as 12% in those with metastases [3].
Although renal cancer can be highly curable if detected at 
an early stage, approximately one-third of patients present with 
locally advanced or metastatic disease at the moment of diagno-
sis [4]. In another third of patients, metastatic disease appears later 
following nephrectomy [2]. Renal cancer usually spreads to the 
lung (75%), soft tissue (36%), bone (20%), liver (18%) and central 
nervous system (8%) [3, 5].
The prognosis for patients with bone metastases is considered 
to be poor, with an average life expectancy of 12–24 months [6]. 
After pelvis, extremities are the second most common localization 
of osseous metastatic lesions in renal carcinoma [6, 7]. However, 
the data on the prognostic value of long bone metastases are 
scarce and inconsistent.
The aim of the study was to assess the prevalence of long 
bone metastases in renal cancer patients and to evaluate their 
utility as predictors of survival in this group.
Materials and methods
This retrospective study included 20 renal cancer patients with 
bone metastases who underwent a series of bone scintigraphy 
examinations.
Bone scintigraphy studies were acquired using dual-head 
hybrid SPECT-CT cameras (Infinia VC Hawkeye 1 or Infinia VC 
Hawkeye 4, General Electric Healthcare). Whole body planar 
images (low energy high resolution collimator, 256 × 256 matrix, 
200 s per projection, 140 kV) were performed 2.5–3 hours after 
740–925 Mbq of 99mTc-methylene diphosphonate was injected. 
The acquisition time was 18–20 minutes.
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Depending on the localization of bone metastases the pa-
tients were divided into group with 1) metastases in the skeleton 
including long bones or with 2) metastases in the axial skeleton 
only. Statistical analysis was performed using t-Student test and 
Mann-Whitney test. Localization-specific survival probability was es-
timated using Kaplan-Meyer curves.
Results
The study included 20 patients (10 men and 10 women) aged 
33–91 years (mean ± SD: 62 ± 19.7 years). Each patient had 
metastatic renal cancer with osseous lesions. The patients were 
followed-up for 4–81 months since the first bone scintigraphy ima-
ging. Eleven deaths (including 8 among patients with long bone 
lesions) were recorded from the moment of disease diagnosis to 
60 months of follow-up. Long bone metastases were observed 
in 10/20 patients (50%). The mean number of bone metasta-
ses was significantly higher in patients with long bone lesions (8.1 
vs 2.3, p < 0.01) (Table 1).
We observed that patients who were alive at the end of the fol-
low-up period had lower total number of metastases as well as long 
bone lesions — 2.7 vs 7.2 (p < 0.04) and 0.3 vs 1.3 (p < 0.05) 
respectively. The mean age of patients who were alive at the end 
of the follow-up period was higher than in the patients who died 
during observation (62.3 vs 54.5 years). However, the difference 
was not statistically significant (Table 2).
Kaplan-Meyer curves, drawn in order to estimate survival 
probability depending on bone metastases localization, show that 
patients with long bone metastases tend to have lower survival prob-
ability than the ones with metastases in the axial skeleton (Fig. 1).
Discussion
The most significant prognostic factors in renal cancer 
patients seem to be the stage, tumour size, Fuhrman grade of 
primary tumour, patient condition, presence of metastases and 
their location [8, 9].
Our data indicates that patients with long bone metastases tend 
to have lower survival probability than the patients with metasta-
ses observed in other bones. Additionally, the patients with long 
bone metastases have more osseous lesions in total. We also ob-
served that the patients who died during the follow-up period were 
younger and had higher number of osseous lesions, including long 
bone metastases. Yet, the authors are of the opinion that precise 
assessment of incremental predictive value of long bone meta-
stases in metastatic renal cancer requires larger group of patients.
The data on the prognostic value of long bone metastases are 
scarce. According to Althausen et al. [6] who studied 38 cases of 
metastatic renal cell carcinoma with secondary osseous meta-
stases there were two factors that appeared highly statistically 
significant in predicting survival — the site of bone metastases and 
the time from renal cancer diagnosis to the first metastasis. The 
authors observed that the outcome was significantly worse if first 
bone lesions appeared in the axial skeleton, and especially the 
Table 1. Comparison of patients with and without long bone metastases
Patients with long bone  
metastases (n = 10)
Patients without long bone  
metastases (n = 10)
Significance
Age [± SD] 55 (± 11,6) 60.9 (±11) ns
Women 5 (50%) 7 (70%) ns
Men 5 (50%) 3 (30%) ns
Total no. of metastases (mean) [± SD] 8.1 (±5) 2.3 (±1.9) p < 0.01
Deaths 8 (73%) 3 (27%) p < 0.05
Table 2. Comparison of dead and surviving patients
Dead patients Surviving patients Significance
Age [± SD] 54.5 (±10) 62.3 (±12) ns
Women 5 7 ns
Men 6 2 ns
Total no. of metastases (mean) [± SD] 7.2 (±5.4) 2.7 (±2.3) p < 0.04
Presence of long bone metastases 8 2 p < 0.03
No. of long bone metastases (mean) [± SD] 1.3 (±1.4) 0.3 (±0.7) P < 0.05
Figure 1. Kaplan-Meyer survival probability curves. Patients with 
long bone metastases tend to have lower survival probability than 
the patients with metastases observed in other bones; TM — axial 
skeleton metastases, TM/LB — axial and appendicular skeleton 
metastases
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pelvis, than if they occurred in the extremity bones (femur, tibia and 
humerus). A worse survival rate was also shown for patients with 
early onset of metastases. Survival for the entire series was 90% 
at 6 months, 84% at 1 year, 55% at 5 years and 39% for 10 years.
In our study the data on the localisation of first metastatic bone 
lesions was unavailable as the patients were not followed-up from 
the time of renal cancer diagnosis but from the first scintigraphic 
examination (which was positive for bone metastases in all patients). 
However, contrarily to Althausen et al. [6] our data suggests that 
patients with both appendicular and axial skeleton lesion have sig-
nificantly worse survival prognosis than the patients with axial skel-
eton lesions only (Fig. 2). We also observed that the patients with 
long bone lesions had significantly higher total number of bone 
metastases than the patients with axial skeleton lesions — the mean 
was 8.1 and 2.3 respectively (p < 0.01) (Table 1).
The literature search also yielded studies that did not show cor-
relation between bone metastases localization and survival. Dineen 
et al. [10] found that metastasis site did not influence survival. The 
study, however, assessed survival in patients after surgical exci-
sion of a solitary metastasis from renal carcinoma. Out study, to 
the contrary, included patients with disseminated osseous lesions.
Retrospective study by Szendröi et al.[4] including 65 renal 
clear cell carcinoma patients operated for bone metastases showed 
that the lesion localization in the skeleton did not correlate with 
the survival neither after renal (p = 0.1787) nor after bone surgery 
(p = 0.4786). The assessed group of patients did not, however, 
include patients with spine metastases which seem to negatively 
influence the survival prognosis. 
Conclusions
Long bone metastases localization may influence survival in 
patients with renal cancer. The incremental prognostic value of long 
bone metastasis needs to be confirmed in larger trial.
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Figure 2. Bone scintigraphy scans in a 64-year-old patient. The first 
positive bone scan (1a, 1b) shows multiple osseous lesions limited to 
the spine. The last bone scintigraphy (performed 2 months before the 
patient’s death) revealed disseminated bone metastases both in the 
axial and the appendicular skeleton (2a, 2b). The patient was followed-
-up for 46 months
